Morepen Labs' board has proposed a final dividend of Re 0.20 per equity share (FV Rs 2) for FY26, pending shareholder approval.

A significant business update includes revising the effective date for its Medical Devices business slump sale to subsidiary Morepen Medipath to April 1, 2026. This transfer, delayed by procedural formalities, is for a lump-sum consideration of ~Rs 197.10 Cr.

The company also approved its audited quarter and year-end financial results for FY26.